Xtant Medical Honors Donor Hero on the Donate Life Rose Parade® Float
Company Among Sponsors of Donate Life Float at 2022 Rose Parade
BELGRADE, Mont., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, honors Samuel Lee Becker, a donor hero, as part of its sponsorship of the 2022 Donate Life Float at the Rose Parade in Pasadena on New Year’s Day.
Sam was forever a giver who gave freely and frequently and had every intention of making the world a better place for everyone. Sam gave his time, money, smile, humor, compassion, empathy, and ultimately, himself. Even as a young person he was passionate about how one could continue to help others even in death. In the years since his passing, his family has learned that through bone and tissue donation, a part of Sam lives on in 109 recipients.
The 2022 Donate Life Rose Parade float titled, Courage to Hope, will be part of the 2022 Rose Parade that will take place in Pasadena, CA on New Year’s Day.
“We are proud to celebrate the life of Sam, whose passion of organ donation and ultimate gift enables others to have a full life,” said Sean Browne, President and CEO of Xtant Medical. “Donation is at the core of our values in bringing hope to patients in need of a life saving transplant from those who are willing to save others. Our support for Sam, Donate Life and Courage to Hope closely aligns with our mission of ‘honoring the gift of donation, by allowing our patients to live as full, and complete a life as possible.’”
Organ, eye and tissue donation offers hope to donor families, who in the midst of losing a loved one, see the chance to believe their loved ones’ gifts will help save others. At the same time, those waiting to receive a lifesaving organ have the dream and the courage to hope that a donor will become available, to restore their health and change their lives. They can now achieve their life’s goals, all thanks to their donors.
As the world’s most visible campaign to inspire organ, eye and tissue donation, The Donate Life Rose Parade float inspires viewers to help the over one million people in need of organ, eye or tissue transplants each year. Register today to become an organ, eye or tissue donor by visiting DonateLife.net.
About Donate Life America (DLA)
Donate Life America (DLA) is a 501(c)3 nonprofit organization leading its national partners and Donate Life State Teams to increase the number of donated organs, eyes and tissues available to save and heal lives. DLA owns, manages and promotes Donate Life℠, the national brand for the cause of donation; motivates the public to register as organ, eye and tissue donors; provides education about living donation; manages the National Donate Life Registry at RegisterMe.org; and develops and executes effective multi-media campaigns to promote donation.
About Xtant Medical Holdings, Inc.
Xtant Medical Holdings, Inc. () is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.
The symbols ™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as “intends,” ‘‘expects,’’ ‘‘anticipates,’’ ‘‘plans,’’ ‘‘believes,’’ ‘‘estimates,’’ “continue,” “future,” ‘‘will,’’ “potential,” “going forward,” similar expressions or the negative thereof, and the use of future dates. Forward-looking statements in this release include the Company’s continued investment in its future through the combination of new product introductions, penetration of underserved markets and further distribution network expansion. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company’s future operating results and financial performance; the ability to increase or maintain revenue; the ability to remain competitive; the ability to innovate and develop new products; the ability to engage and retain new and existing independent distributors and qualified personnel; the effect of the COVID-19 pandemic on the Company’s business, operating results and financial condition; the Company’s ability to implement successfully its future growth initiatives; government and third-party coverage and reimbursement for Company products; the ability to obtain and maintain regulatory approvals and comply with government regulations; the effect of product liability claims and other litigation to which the Company may be subject; the effect of product recalls and defects; the ability to obtain and protect Company intellectual property and proprietary rights and operate without infringing the rights of others; the ability to service Company debt, comply with its debt covenants and access additional indebtedness; the ability to obtain additional financing on favorable terms or at all; and other factors. Additional risk factors are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission (SEC) on February 24, 2021 and subsequent SEC filings by the Company, including without limitation its most recent Quarterly Report on Form 10-Q for the quarter ended June 30, 2021 filed with the SEC. Investors are encouraged to read the Company’s filings with the SEC, available at , for a discussion of these and other risks and uncertainties. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement.
Investor Relations Contact
David Carey
Lazar FINN
Ph: 212-867-1762
Email:
A photo accompanying this announcement is available at
